ScoreWhy is Sprint Bioscience AB ?
1
With a growth in Net Sales of 723.19%, the company declared Outstanding results in Dec 25
- The company has declared positive results in Jan 70 after 2 consecutive negative quarters
- OPERATING CASH FLOW(Y) Highest at SEK 83.53 MM
- ROCE(HY) Highest at 142.84%
- RAW MATERIAL COST(Y) Fallen by -333.72% (YoY)
2
With ROE of -156.77%, it has a risky valuation with a 5.37 Price to Book Value
- Over the past year, while the stock has generated a return of 218.16%, its profits have fallen by -252.4%
3
Market Beating performance in long term as well as near term
- Along with generating 218.16% returns in the last 1 year, the stock has outperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Sprint Bioscience AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sprint Bioscience AB for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Sprint Bioscience AB
218.16%
0.38
137.02%
OMX Stockholm 30
10.97%
0.59
18.59%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
58.16%
EBIT Growth (5y)
34.70%
EBIT to Interest (avg)
-23.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.17
Sales to Capital Employed (avg)
5.26
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
7.10%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.37
EV to EBIT
-2.35
EV to EBITDA
-2.45
EV to Capital Employed
-5.04
EV to Sales
0.88
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-156.77%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend43What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK 83.53 MM
ROCE(HY)
Highest at 142.84%
RAW MATERIAL COST(Y)
Fallen by -333.72% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 18.22 times
NET SALES(Q)
Highest at SEK 133.91 MM
OPERATING PROFIT(Q)
Highest at SEK 117.81 MM
OPERATING PROFIT MARGIN(Q)
Highest at 87.98 %
PRE-TAX PROFIT(Q)
Highest at SEK 113.17 MM
NET PROFIT(Q)
Highest at SEK 113.17 MM
EPS(Q)
Highest at SEK 1.07
-8What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at 0 %
INTEREST(Q)
Highest at SEK 4.67 MM
Here's what is working for Sprint Bioscience AB
Net Sales
At SEK 133.91 MM has Grown at 723.19%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (SEK MM)
Pre-Tax Profit
At SEK 113.17 MM has Grown at 2,787.58%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (SEK MM)
Net Profit
At SEK 113.17 MM has Grown at 2,787.58%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (SEK MM)
Operating Cash Flow
Highest at SEK 83.53 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Net Sales
Highest at SEK 133.91 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (SEK MM)
Operating Profit
Highest at SEK 117.81 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (SEK MM)
Operating Profit Margin
Highest at 87.98 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at SEK 113.17 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (SEK MM)
Net Profit
Highest at SEK 113.17 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (SEK MM)
EPS
Highest at SEK 1.07
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (SEK)
Debtors Turnover Ratio
Highest at 18.22 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -333.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Sprint Bioscience AB
Interest
At SEK 4.67 MM has Grown at inf%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Interest
Highest at SEK 4.67 MM
in the last five periods and Increased by inf% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Debt-Equity Ratio
Highest at 0 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
